Literature DB >> 18469192

FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction.

Shawn A Morales1, Sergey Mareninov, Madhuri Wadehra, Lily Zhang, Lee Goodglick, Jonathan Braun, Lynn K Gordon.   

Abstract

PURPOSE: Proliferative vitreoretinopathy (PVR) occurs in approximately 10% of patients after retinal detachment. PVR results from a multiphase process that leads to an aberrant wound-healing strategy with contractile cellular forces and tractional retinal detachment (TRD). Epithelial membrane protein (EMP) 2 controls cell surface expression and function of integrin isoforms associated with cellular contraction in many cell types. Since EMP2 is highly expressed in retinal pigment epithelium, this study investigates the role of EMP2 in collagen gel contraction.
METHODS: EMP2 expression was recombinantly modified in the ARPE-19 cell line. Cell surface integrin expression was assessed by flow cytometry. Collagen gel contraction was assessed by using an in vitro assay and the percentage of contraction was quantified. Proliferation and migration were measured by BrdU incorporation and a wound-healing assay, respectively. Cellular invasion was investigated with polycarbonate membranes coated with collagen.
RESULTS: EMP2 expression levels correlated positively with the ability to contract collagen gels. Compared with wild-type ARPE-19 cells, the cells with increased EMP2 expression exhibited enhanced contraction (P = 0.02), and decreased EMP2 expression concomitantly resulted in decreased contraction (P = 0.002). EMP2 overexpression resulted in reduced proliferation, migration, and integrin alpha1 and alpha2 integrin expression. EMP2 overexpression was associated with a 70% increase in FAK activation (P = 0.0003) and relative resistance of gel contraction to inhibitors of FAK/Src activation.
CONCLUSIONS: ARPE-19-mediated collagen gel contraction is a multistep process that requires integrin ligation and activation of the FAK/Src complex. EMP2 positively modulates collagen gel contraction by ARPE-19 cells through increased FAK activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18469192      PMCID: PMC3752991          DOI: 10.1167/iovs.07-1598

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  37 in total

1.  Enhancement of dedifferentiation and myoid differentiation of retinal pigment epithelial cells by platelet derived growth factor.

Authors:  A Ando; M Ueda; M Uyama; Y Masu; S Ito
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

Review 2.  Tetraspanins.

Authors:  C Boucheix; E Rubinstein
Journal:  Cell Mol Life Sci       Date:  2001-08       Impact factor: 9.261

3.  Transient activation of the c-Jun N-terminal kinase (JNK) activity by ligation of the tetraspan CD53 antigen in different cell types.

Authors:  Mónica Yunta; José L Oliva; Ramiro Barcia; Vaclav Horejsi; Paula Angelisova; Pedro A Lazo
Journal:  Eur J Biochem       Date:  2002-02

4.  Epithelial membrane protein-2 regulates surface expression of alphavbeta3 integrin in the endometrium.

Authors:  Madhuri Wadehra; Ashley Forbes; Natasha Pushkarna; Lee Goodglick; Lynn K Gordon; Carmen J Williams; Jonathan Braun
Journal:  Dev Biol       Date:  2005-10-10       Impact factor: 3.582

5.  Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells.

Authors:  R P Casaroli-Marano; R Pagan; S Vilaró
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-08       Impact factor: 4.799

6.  Mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K) pathways differently regulate retinal pigment epithelial cell-mediated collagen gel contraction.

Authors:  Hajime Bando; Yasushi Ikuno; Yuichi Hori; Kaori Sayanagi; Yasuo Tano
Journal:  Exp Eye Res       Date:  2005-11-10       Impact factor: 3.467

7.  Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity.

Authors:  C X Wang; M Wadehra; B C Fisk; L Goodglick; J Braun
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

8.  Knockdown of the tetraspan protein epithelial membrane protein-2 inhibits implantation in the mouse.

Authors:  Madhuri Wadehra; Molina Dayal; Monica Mainigi; Teri Ord; Ramaswamy Iyer; Jonathan Braun; Carmen J Williams
Journal:  Dev Biol       Date:  2006-02-20       Impact factor: 3.582

9.  Contraction of collagen matrices mediated by alpha2beta1A and alpha(v)beta3 integrins.

Authors:  M E Cooke; T Sakai; D F Mosher
Journal:  J Cell Sci       Date:  2000-07       Impact factor: 5.285

Review 10.  Specific tetraspanin functions.

Authors:  M E Hemler
Journal:  J Cell Biol       Date:  2001-12-24       Impact factor: 10.539

View more
  26 in total

1.  Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells.

Authors:  Shawn A Morales; David G Telander; Sergey Mareninov; Agnes Nagy; Madhuri Wadehra; Jonathan Braun; Lynn K Gordon
Journal:  Exp Eye Res       Date:  2012-06-19       Impact factor: 3.467

2.  Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2).

Authors:  Shawn A Morales; Sergey Mareninov; Paige Coulam; Madhuri Wadehra; Lee Goodglick; Jonathan Braun; Lynn K Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-03       Impact factor: 4.799

Review 3.  Regulation of FAK Activity by Tetraspan Proteins: Potential Clinical Implications in Cancer.

Authors:  Yu Qin; Shabnam Mohandessi; Lynn Gordon; Madhuri Wadehra
Journal:  Crit Rev Oncog       Date:  2015

Review 4.  Review of the GAS3 Family of Proteins and their Relevance to Cancer.

Authors:  Negin Ashki; Lynn Gordon; Madhuri Wadehra
Journal:  Crit Rev Oncog       Date:  2015

5.  Epithelial membrane protein 2 controls VEGF expression in ARPE-19 cells.

Authors:  Shawn A Morales; David G Telander; Deanna Leon; Krisztina Forward; Jonathan Braun; Madhuri Wadehra; Lynn K Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-28       Impact factor: 4.799

6.  Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer.

Authors:  Maoyong Fu; Erin L Maresh; Robert A Soslow; Mohammad Alavi; Vei Mah; Qin Zhou; Alexia Iasonos; Lee Goodglick; Lynn K Gordon; Jonathan Braun; Madhuri Wadehra
Journal:  Clin Cancer Res       Date:  2010-08-01       Impact factor: 12.531

7.  Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.

Authors:  Maoyong Fu; Erin L Maresh; Gustavo F Helguera; Meagan Kiyohara; Yu Qin; Negin Ashki; Tracy R Daniels-Wells; Najib Aziz; Lynn K Gordon; Jonathan Braun; Yahya Elshimali; Robert A Soslow; Manuel L Penichet; Lee Goodglick; Madhuri Wadehra
Journal:  Mol Cancer Ther       Date:  2014-01-21       Impact factor: 6.261

8.  Epithelial membrane protein 2 (EMP2) deficiency alters placental angiogenesis, mimicking features of human placental insufficiency.

Authors:  Carmen J Williams; Alison Chu; Wendy N Jefferson; David Casero; Deepthi Sudhakar; Nevil Khurana; Claire P Hogue; Chinmayi Aryasomayajula; Priya Patel; Peggy Sullivan; Elizabeth Padilla-Banks; Shabnam Mohandessi; Carla Janzen; Madhuri Wadehra
Journal:  J Pathol       Date:  2017-05-03       Impact factor: 7.996

9.  Rewiring integrin-mediated signaling and cellular response with the peripheral myelin protein 22 and epithelial membrane protein 2 components of the tetraspan web.

Authors:  Shawn A Morales; David Telander; Lucia Notterpek; Madhuri Wadehra; Jonathan Braun; Lynn K Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-23       Impact factor: 4.799

10.  A novel function of p53: a gatekeeper of retinal detachment.

Authors:  Hetian Lei; Marc-Andre Rheaume; Jing Cui; Shizuo Mukai; David Maberley; Arif Samad; Joanne Matsubara; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.